IsoTis snaps up GenSci after Osteotech settlement
This article was originally published in Clinica
Executive Summary
The sales and marketing synergies offered by a merger with GenSci OrthoBiologics and underlying industry growth should lead to IsoTis reaching profitability in 2005. So said the Swiss-Dutch company said after announcing its intention to acquire the Irvine, California operating subsidiary of Toronto, Canada-based bioimplant firm GenSci Regeneration Sciences. The firms will be targeting the bone void filler market, which was worth around $300m in 2002.